This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Immunomedics Announces Presentations At Upcoming Conferences

MORRIS PLAINS, N.J., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the Company will be making multiple presentations at 3 upcoming scientific and medical conferences.

At the World ADC San Francisco 2013, scheduled for October 14-17, 2013 in San Francisco, CA, Cynthia L. Sullivan, President and Chief Executive Officer, will present "The Growth Potential for using ADCs: Diverse Cancer Types," including the IMMU-130, IMMU-132 and IMMU-110 program descriptions, during the Commercial Leader's Day session on Monday, October 14, at 9:30 a.m. In addition, Dr. David M. Goldenberg, Chairman, Chief Scientific Officer, and Chief Medical Officer, will report "First Clinical Results of SN-38 ADCs in Solid Tumor Therapy" in the Plenary Session: Early Clinical Trial Results on Wednesday, October 16, at 4:30 p.m.

The Company and its collaborators will present 6 studies at the 26 th Annual Congress of the European Association of Nuclear Medicine to be held in Lyon, France, from October 19-23, 2013. The schedule and meeting places for the presentations, together with the abstract number and session title, are listed below:
  • "Preclinical evaluation of Al 18F- and 68Ga-labeled GRPR-antagonist for PET imaging of gastrin-releasing peptide receptor expression in prostate cancer" [Abstract No. OP060, Oral Session Title: Radiopharmaceuticals & Radiochemistry & Dosimetry: PET Radiopharmaceuticals, Sunday, October 20, 11:41 a.m. – 11:52 a.m., Room: Rhône 3A/3B]
  • "SPECT/fluorescence dual-modality imaging of carcinoembryonic antigen-expressing tumors: a pretargeting study" [Abstract No. OP261, Oral Session Title: Featured - Molecular & Multimodality Imaging: Optical Imaging, Monday, October 21, 12:29 p.m. – 12:40 p.m., Room:  Auditorium Pasteur]
  • "A Phase Ιb study of fractionated 90Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer after ≥ 2 prior therapies" [Abstract No. OP670, Oral Session Title: Radionuclide Therapy & Dosimetry: Miscellaneous Therapy, Wednesday, October 23, 8:00 a.m. – 8:11 a.m., Room:  Gratte-Ciel 1/2/3]
  • "Radioimmunotherapy (RAIT) with anti-CD22 90Y-epratuzumab in adults with refractory or relapsed CD22+ ALL: preliminary results of a phase I/II study" [Abstract No. OP675, Oral Session Title: Radionuclide Therapy & Dosimetry: Miscellaneous Therapy, Wednesday, October 23, 8:55 a.m. – 9:06 a.m., Room: Gratte-Ciel 1/2/3]
  • "Pharmacokinetics of yttrium-90-labeled epratuzumab in the consolidation radioimmunotherapy of non-Hodgkin's lymphoma" [Abstract No. P400, Poster Session Title: Therapy & Clinical Trials: Radioisotope Therapy - Miscellaneous, Sunday, October 20, 4:00 p.m. – 4:30 p.m., Room:  Poster Exhibition Area]
  • "Anti-CEA antibody fragments labeled with [ 18F]AlF for PET imaging of CEA-expressing tumors" [Abstract No. PW138, Poster Session Title: Poster Walk 14 - Radiopharmaceuticals & Radiochemistry & Dosimetry: Antibodies & Peptides, Tuesday, October 22, 9:15 a.m. – 9:20 a.m., Room: Poster Exhibition Area]

Finally, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA, from October 19-23, 2013, a poster on "Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience" will be presented in Poster Session C: Clinical Trials 3 on Tuesday, October 22, at 12:30 p.m. - 3:00 p.m. in Exhibit Hall C-D.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%
TSLA $247.54 -0.07%
YHOO $36.59 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs